CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative

European Journal of Immunology

Volumn 34, Issue 2, 2004, Pages 336-344

  Ghiringhelli, François ^a   Larmonier, Nicolas ^a   Schmitt, Elise ^a   Parcellier, Arnaud ^a   Cathelin, Dominique ^a   Garrido, Carmen ^a   Chauffert, Bruno ^a   Solary, Eric ^a   Bonnotte, Bernard ^a   Martin, François ^a  

^a INSERM   (France)

Author keywords

Cyclosphosphamide; Regulatory T cells; Rodent; Tumor immunity

Indexed keywords

CD4 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; INTERLEUKIN 2 RECEPTOR; METHOTREXATE; METHYLPREDNISOLONE; TRANSFORMING GROWTH FACTOR BETA; VINBLASTINE; ALKYLATING AGENT; GAMMA INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRAFT; CANCER IMMUNOTHERAPY; CARCINOMA CELL; CELL CLONE; CELL CONTACT; CELL ISOLATION; COLON CARCINOMA; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG SENSITIZATION; EFFECTOR CELL; GRAFT REJECTION; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE DEPLETION; LYMPHOCYTE FUNCTION; LYMPHOID TISSUE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; T LYMPHOCYTE; TUMOR CELL; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR REGRESSION; TUMOR VOLUME; ANIMAL; COLON TUMOR; CYTOTOXICITY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOLOGY; IMMUNOTHERAPY; LYMPH NODE; METABOLISM; SPLEEN; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD4; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL LINE, TUMOR; COLONIC NEOPLASMS; CYCLOPHOSPHAMIDE; CYTOTOXICITY, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNE TOLERANCE; IMMUNOTHERAPY; INTERFERON TYPE II; LYMPH NODES; RATS; RECEPTORS, INTERLEUKIN-2; SPLEEN; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES;

EID: 1642378018     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/eji.200324181     Document Type: Article

References (27)

1. Staveley-O'Carroll, K., Sotomayor, E., Montgomery, J., Borrello, I., Hwang, L., Fein, S., Pardoll, D. and Levitsky, H., Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA 1998. 95: 1178-1183.
2. Berendt, M. J. and North, R. J., T cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor. J. Exp. Med. 1980. 151: 69-80.
3. Smyth, M. J., Godfrey, D. I. and Trapani, J. A., A fresh look at tumor immunosurveillance and immunotherapy. Nat. Immunol. 2001. 2: 293-299.
4. Feinberg, M. B. and Silvestri, G., Ts cells and immune tolerance induction: a regulatory renaissance? Nat. Immunol. 2002. 3: 215-217.
5. Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M. and Toda, M., Immunologic self tolerance maintained by activated T cells expressing IL2 receptor α chain (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 1995. 155: 1151-1164.
6. Stephens, L. A. and Mason, D., CD25 is a marker for CD4+ thymocytes that prevent autoimmune diabetes in rats, but peripheral T cells with this function are found in both CD25+ and CD25-subpopulations. J. Immunol. 2000. 165: 3105-3110.
7. Jonuleit, H., Schmitt E., Stassen, M., Tuettenberg, A., Knop, J. and Enk, A. H., Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J. Exp. Med. 2001. 193: 1285-1294.
8. Shevach, E. M., CD4+CD25+ suppressor T cells: more questions than answers. Nat. Rev. Immunol. 2002. 2: 389-400.
9. Sakaguchi, S., Sakaguchi, N., Shimizu, J., Yamazaki, S., Sakihama, T., Itoh, M., Kuniyasu, Y., Nomura, T., Toda, M. and Takahashi, T., Immunologic tolerance maintained by CD25+CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev. 2001. 182: 18-32.
10. Shimizu, J., Yamazaki, S. and Sakaguchi, S., Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 1999. 163: 5211-5218.
11. Onizuka, S., Tawara, I., Shimizu, J., Sakaguchi, S., Fujita, T. and Nakayama, E., Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res. 1999. 59: 3128-3133.
12. Golgher, D., Jones, E., Powrie, F., Elliott, T. and Gallimore, A., Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur. J. Immunol. 2002. 32: 3267-3275.
13. Sutmuller, R. P., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N., Wildenberg, M. E., Allison, J. P., Toes, R. E., Offringa, R. and Melief, C. J., Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocytes responses. J. Exp. Med. 2001. 194: 823-832.
14. Steitz, J., Brück, J., Knop, J. and Tüting, T., Depletion of CD25+CD4+ T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon-α -induced, CD8+ T cell-dependent immune defense of B16 melanoma. Cancer Res. 2001. 61: 8643-8646.
15. Caignard, A., Pelletier, H. and Martin, F., Specificity of the immune response leading to protection or enhancement by regressive and progressive variants of a rat colon carcinoma. Int. J. Cancer 1988. 42: 883-886.
16. Bonnotte, B., Larmonier, N., Favre, N., Fromentin, A., Moutet, M., Martin, M., Gurbuxani, S., Solary, E., Chauffert, B. and Martin, F., Identification of tumor-infiltrating macrophages as the killers of tumor cells after immunization in a rat model system. J. Immunol. 2001. 167: 5077-5083.
17. Woo, E. Y., Chu, C. S., Goletz, T. J., Schlienger, K., Yeh, H., Coukos, G., Rubin, S. C., Kaiser, L. R. and June, C. H., Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J. Immunol. 2002. 168: 4272-4276.
18. Liyanage, U. K., Moore, T. T., Joo, H. G., Tanaka, Y., Herrmann, V., Doherty, G., Drebin, J. A., Strasberg, S. M., Eberlein, T. J., Goedegebuure, P. S. and Linehan, D. C., Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 2002. 169: 2756-2761.
19. Wolf, A. M., Wolf, D., Steurer, M., Gastl, G., Gunsilius, E. and Grubeck-Loebenstein, B., Increase in regulatory T cells in the peripheral blood of cancer patients. Clin. Cancer Res. 2003. 9: 606-612.
20. Lin, C. H. and Hünig, T., Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist. Eur. J. Immunol. 2003. 33: 626-638.
21. Chen, W. J. and Wahl, S. M., TGF-β: the missing link in CD4+CD25+ regulatory T cell-mediated immunosuppression. Cytokine Growth Factor Rev. 2003. 14: 85-89.
22. Bonnotte, B., Favre, N., Moutet, M., Fromentin, A., Solary, E., Martin, M. and Martin, F., Bcl-2-mediated inhibition of apoptosis prevents immunogenicity and restores tumorigenicity of spontaneously regressive tumors. J. Immunol. 1998. 161: 1433-1438.
23. Polak, L. and Turk, J. L., Reversal of immunological tolerance by cyclophosphamide through inhibition of suppressor cell activity. Nature 1974. 249: 654-656.
24. Bard, D. and Mastrangelo, M. J., Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T cells. Cancer Res. 1988. 48: 1671-1675.
25. North, R. J. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J. Exp. Med. 1982. 155: 1063-1074.
26. Vermorken, J. B., Claessen, A. M., van Tinteren, H., Gall, H. E., Ezinga, R., Meijer, S., Scheper, R. J., Meijer, C. J., Bloemena, E., Ransom, J. H., Hanna, M. G. and Pinedo, H. M., Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 1999. 353: 345-350.
27. Chaux, P., Favre, N., Martin, F. and Martin, M. S., Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats. Int. J. Cancer 1997. 72: 619-624.